No Benefit To Kidney Transplant Recipients Found In Large, Randomized, Placebo-Controlled Trial Of Angiotensin II Blockade

FG_AUTHORS: Medical News Today

Main Category: Transplants / Organ Donations
Also Included In: Urology / Nephrology
Article Date: 13 Jan 2013 - 0:00 PST

Current ratings for:
No Benefit To Kidney Transplant Recipients Found In Large, Randomized, Placebo-Controlled Trial Of Angiotensin II Blockade


Healthcare Prof:No Benefit To Kidney Transplant Recipients Found In Large, Randomized, Placebo-Controlled Trial Of Angiotensin II Blockade

A drug that protects the kidneys of patients with chronic kidney disease does not seem to provide the same benefit to kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Immunosuppressants help prolong the function of transplanted organs, but therapies that target non-immunological damage to these organs - such as elevated blood pressure and tissue scarring (or fibrosis) - have not been studied.

Angiotensin II blockade, which causes blood vessels to dilate, can slow the progression of kidney disease in individuals without kidney transplants. Hassan Ibrahim, MD (University of Minnesota) and his colleagues set out to test the strategy in transplant recipients. "To our knowledge this is the first randomized placebo-controlled trial of angiotensin II blockade in these patients," said Dr. Ibrahim.

The investigators assigned 153 kidney transplant recipients to receive the angiotensin II receptor blocker losartan or placebo within three months of transplantation, continuing treatment for five years.

"Contrary to what has been observed in native kidney disease, angiotensin II blockade did not demonstrate a statistically significant benefit in lessening fibrosis or terminal kidney failure from severe fibrosis. Nevertheless, angiotensin II blockade was safe and well-tolerated," said Dr. Ibrahim. He noted that a similar trial is ongoing in Canada.

The findings provide valuable information for future studies of non-immunological therapies for kidney transplant recipients.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our transplants / organ donations section for the latest news on this subject.
Study co-authors include Scott Jackson, MS, Jeffrey Connaire, MD, Arthur Matas, MD, Arthur Ney, MD, Ann West, RN, Nicole Lentsch, RN, Jensina Ericksen, Jenny Bodner, RN, Bertram Kasiske, MD, FACP (Hennepin County Medical Center); Behzad Najafian, MD (University of Washington); and Michael Mauer, MD (University of Minnesota).

Disclosures: The study was sponsored by NIDDK (grant #U01 DK060706-09). The drug and placebo were provided by Merck Pharmaceuticals.

The article, entitled "Angiotensin II Blockade in Kidney Transplant Recipients" doi: 10.1681/2012080777.

American Society of Nephrology

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "No Benefit To Kidney Transplant Recipients Found In Large, Randomized, Placebo-Controlled Trial Of Angiotensin II Blockade." Medical News Today. MediLexicon, Intl., 13 Jan. 2013. Web.
13 Jan. 2013. <http://www.medicalnewstoday.com/releases/254827.php>


APA

Please note: If no author information is provided, the source is cited instead.


Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Read more http://www.medicalnewstoday.com/releases/254827.php

PUA Social Network

Twitter Facebook

Contact us

The Philippine Urological Association,Inc
3rd floor. PCS Bldg., 992 EDSA, Quezon City,
Metro Manila, PHILIPPINES 1105
View Map

+632-9256740 
+632-4544439
+63917-5244456

eMail us